Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Pain in the middle eight

This article was originally published in Scrip

Executive Summary

In popular music parlance, the middle eight is the part of a song that is not a chorus or a verse. In America, it's called the bridge, although it can also be thought of as either the padding or less memorable parts of a music track. If life science companies were to be classified as either chorus, verse or middle eight companies, profitable biotechnology companies like Gilead Sciences and Celgene (which we own), that have attained the size that means they may never be acquired, would be the verses, while the chorus would include those companies like Regeneron Pharmaceuticals (which we own) and Alexion Pharmaceuticals that have easily surpassed profitability, but are not yet so big that they could never be acquired.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC025620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel